Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864904 | 0.86 | AGTR1 (0.60) | AGTR2AGTR1 | |
| SCHEMBL13262878 | 0.85 | AGTR2 (0.56) | AGTR2AGTR1 | |
| SCHEMBL13196536 | 0.84 | AGTR2 (0.55) | AGTR2AGTR1 | |
| SCHEMBL11098564 | 0.82 | AGTR1 (0.55) | AGTR2AGTR1 | |
| SCHEMBL29308427 | 0.74 | AGTR2 (0.65) | AGTR2AGTR1 | |
| SCHEMBL9194373 | 0.74 | AGTR1 (1.00) | AGTR2AGTR1 | |
| SCHEMBL708 | 0.73 | AGTR1 (0.80) | AGTR2AGTR1 | |
| SCHEMBL8565506 | 0.72 | AGTR2 (0.69) | AGTR2AGTR1 | |
| SCHEMBL9468705 | 0.72 | AGTR1 (0.78) | AGTR2AGTR1 | |
| SCHEMBL30543045 | 0.71 | ALDH1A1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563586-B2 | 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation | ELDRUG S.A. (GR) | 2013-10-22 | — | — | US | disclosed |
| US-20100216854-A1 | 1,3 AND 1,3,5 SUBSTITUTED IMIDAZOLES AS ANTIHYPERTENSIVES | ELDRUG S.A. (GR) | 2010-08-26 | — | — | US | disclosed |
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | ELDRUG S.A. (GR) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216854-A1 | 1,3 AND 1,3,5 SUBSTITUTED IMIDAZOLES AS ANTIHYPERTENSIVES | AGTR1, AGTR2, ADRB3 | AGTR2 2/4885AGTR1 1/4885 |
| US-20100166837-A1 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION | AGTR1, AGTR2, AGT | AGTR2 2/4885AGTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.